IBERE PHARMACEUTICALS Quarterly Nonoperating Income (Expense) in USD from Q1 2021 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Ibere Pharmaceuticals quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2021 to Q3 2022.
  • Ibere Pharmaceuticals Nonoperating Income (Expense) for the quarter ending September 30, 2022 was $1.02M, a 50% decline year-over-year.
  • Ibere Pharmaceuticals Nonoperating Income (Expense) for the twelve months ending September 30, 2022 was $7.22M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 $7.22M $1.02M -$1.02M -50% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $8.25M $1.61M +$1.49M +1228% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-12
Q1 2022 $6.75M $3.88M +$4.19M Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $2.57M $709K Oct 1, 2021 Dec 31, 2021 10-K 2022-03-31
Q3 2021 $2.05M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $121K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$311K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.